The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About
    • Mission & Activities
    • Directors and Officers
    • The Antibody Society’s Committees
      • AIRR Community Committee
      • Communication & Membership Committee
      • Meetings Committee
    • Sponsors & Partners
  • Society meetings
    • Harnessing Cytokines for Cancer Immunotherapy Symposium
    • Biopharmaceutical Informatics Symposium
    • Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells Symposium
    • Emerging Immunotherapeutics for Ovarian Cancer Symposium
    • AIRR Community Meetings
    • Antibody Engineering & Therapeutics (US) 2023
      • 2022 Antibody Engineering & Therapeutics
      • 2020 Antibody Engineering & Therapeutics
      • 2019 Antibody Engineering & Therapeutics
      • 2018 Antibody Engineering & Therapeutics
      • What is INN a Name?
        • INN issue updates
    • Antibody Engineering & Therapeutics Europe 2023
    • FOCIS Symposia
  • AIRR Community
    • AIRR News
    • AIRR Publications
    • AIRR Meetings
      • AIRR Community Special Event 2023  – Zooming in to the Community II
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-committees
      • Communications Sub-committee
      • Executive Sub-committee
      • Inferred Allele Review Committee
      • Meetings Sub-committee
    • AIRR Data Commons
    • AIRR Community Calendar
    • AIRR Community Webinar Series
    • On AIRR – An AIRR Community Podcast
    • AIRR Community Resources
    • AIRR Community Service Prize 2022
  • Members only
    • Login
    • Note to members
    • Member discount codes
    • 2023 Calendar of Events
    • James S. Huston Antibody Science Talent Award
      • 2021 James S. Huston Antibody Science Talent Award Recipient
      • 2020 James S. Huston Antibody Science Talent Award Recipient
      • JSH Award Criteria
    • Science Writing Competition
      • Science Writing Competition Winners
    • Imaging Competition
    • Research Competitions
      • Research Competition Winners
    • Antibodies in early-stage studies
    • Presentations
  • Upcoming meetings
  • Web Resources
    • Society Publications
    • Antibody News
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies in late-stage clinical studies
    • Research Resources
    • Education Resources
  • Career Center
    • Career Shorts
  • Learning Center
    • Upcoming Webinars
    • Snakebite antivenoms: Global challenges and progress toward recombinant antibody therapeutics
    • Adaptive Immune Receptor Repertoires
    • Antibody Discovery & Development
    • Commercializing Antibody Therapeutics
    • Antibodies to Watch
    • Antibody Validation
  • COVID-19
    • Guide to “Coronavirus in the Crosshairs”
    • COVID-19 Biologics Tracker
    • Meeting Report: The Diagnostic Landscape for COVID-19
You are here: Home / Snakebite antivenoms: Global challenges and progress toward recombinant antibody therapeutics

Snakebite antivenoms: Global challenges and progress toward recombinant antibody therapeutics

Puff adder (Bitis arietans)

Every year, 2.7 million people are bitten by venomous snakes, causing over 130,000 deaths and 400,000 permanent disablements that disproportionally occur among the poor. The unavailability of effective snakebite antivenoms is thus a severe and neglected worldwide problem. Using methods developed over a hundred years ago, most antivenom therapies are still derived from horses, which produce polyclonal antibodies when injected with the snake venom. Developing recombinant products is challenging, however, due to the wide variety of venomous snakes and the extensive heterogeneity and unknown components of snake toxins, which differ between snake species and among species found in different regions. In addition, injecting horse-derived proteins into humans may result in anaphylaxis, serum sickness and inflammation. Innovative treatments for tropical snakebite are urgently needed, and we hope that this Symposium will inspire new collaborations, thereby enabling critical new developments in combating this complex, challenging and important public health issue.

Pictured, from left to right: Paul Parren, Andreas Hougaard Laustsen, Nicolas Casewell, John McCafferty, Manuela Pucca and Abdulraqaz Habib.

Session Chairs:

Prof. Abdulrazaq Habib (Bayero University, Kano, Nigeria)

Prof. Paul W.H.I. Parren (Leiden University Medical Center, Leiden and LAVA Therapeutics, Utrecht, the Netherlands)

Agenda:

Chairperson’s introduction Prof. Paul W.H.I. Parren, The Antibody Society & Leiden University Medical Center, Netherlands

View video recording here

Global challenges of Snakebite Antivenom Therapy Speaker: Prof. Abdulrazaq Habib, Bayero University in Kano, Nigeria

Polyclonal antivenom remains the mainstay of snakebite envenoming therapy although adverse reactions often follow its administration. While it is efficacious in many patients with coagulopathy, effect is not durable with Fab format, and it is relatively ineffective against necrosis and neurotoxicity. Despite favorable antivenom cost-effectiveness there are challenges with access, financing, potency, quality, standardization, supply and utilization.

View video recording here
View Prof. Habib’s slides

Therapeutic antibodies against snake venoms therapy Speaker: Prof. Nicolas Casewell, Centre for Snakebite Research & Interventions, Liverpool School of Tropical Medicine, Liverpool, UK

Snake venoms are mixtures of toxins that vary extensively between and within snake species. This variability has serious consequences for the management of the world’s 1.8 million annual snakebite victims, and negatively impacts upon the cross-species efficacy of polyclonal antibody therapies known as antivenom. In this talk I will discuss how the diversity of drug targets present in venom cause major challenges for the therapeutic utility of polyclonal antibody treatments, and how knowledge of venom variation can be used to help inform appropriate antivenom use.

View video recording here
View Prof. Casewell’s slides

Snakebite venom variation and its impact on the efficacy of polyclonal antibody Speaker: Prof. Manuela Pucca, Medical School, Federal University of Roraima – Brasil

In Brazil, snakebites are considered a global neglected disease, presenting more than 28,000 bites each year, with high impact in the Brazilian Amazon. Currently, antivenoms based on polyclonal antibodies produced in horses are the only specific treatment. The majority (~70%) of the antibodies in most antivenoms, however, are not directed against venom components, and the remaining 30% of horse-derived antibodies may not neutralize important toxins. To address this problem, new antibody discovery technologies, antibody engineering approaches, and antibody manufacturing processes have been applied to generating antivenoms. In this presentation, the snakebite neglected problem in the Brazilian Amazon will be discussed. Past, present, and future production of antivenoms will be outlined, and advances in the next generation of antivenoms will be presented. In addition, the Amazonia Snakebite Initiative will be announced.

View video recording here
View Prof. Pucca’s slides

Can we ‘deconvolute’ polyclonal antivenoms to create defined antibody cocktails? Speaker: Dr. John McCafferty, IONTAS, UK

Equine polyclonal antibodies such as “EchiTab-plus-ICP”, used in sub-Saharan Africa save lives of snakebite victims. This century-old approach however requires injection of grams of an ill-defined, variable mix of non-human protein to snakebite victims. There is an opportunity in revolutionising anti-venom treatment by using recombinant antibody technology to identify and combine the active components from polyclonal antivenom responses. This presentation will review the opportunities and challenges.

View video recording here
View Dr. McCafferty’s slides

Recombinant antivenom based on oligoclonal broadly neutralizing antibodies Speaker: Prof. Andreas Hougaard Laustsen, Department of Biotechnology and Biomedicine, Technical University of Denmark, Lyngby, Denmark

Snakebite envenomings are serious medical emergencies that are currently still treated with polyclonal antibodies derived from the plasma of immunized animals. With the advent of recombinant DNA technology and the many advances that have taken place within antibody discovery methods, an opportunity now presents itself to modernize envenoming therapy. Here, recent progress and perspectives in the discovery and use of oligoclonal broadly-neutralizing antibodies against snake venoms will be presented.

View video recording here
View Prof. Hougaard Laustsen’s slides

Panel discussion Speakers: All

View video recording here

mabs

mabs

The Official Journal of The Antibody Society

Career Center

Our Career Center is a premier resource to connect highly qualified talent with matching career opportunities. Visit for details on over 800 jobs!

AIRR Community

AIRR Community

The Adaptive Immune Receptor Repertoire Community is a research-driven group organizing around the use of high-throughput sequencing technologies to study antibody/B-cell and T-cell receptor repertoires.

Recent Posts

  • FDA approves Zynyz™ (retifanlimab-dlwr) for Merkel cell carcinoma March 23, 2023
  • Ultralong CDR H3-based knobs: the smallest antibody fragment March 6, 2023
  • TRUST4 is now certified as AIRR-compliant March 1, 2023

Archives

Follow us online

  • Email
  • LinkedIn
  • Twitter
  • YouTube
  • Home
  • Privacy & Terms of Use
  • About
  • Directors and Officers
  • Advisors
  • Sponsors & Partners
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members only
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals